Effectiveness and safety of a glutaraldehyde-modified, L-tyrosine-adsorbed and monophosphoryl lipid A-Adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen: A retrospective, controlled real-world study
Background: Allergy to olive pollen is one of the primary causes of allergic asthma in Spain. Even though allergen immunotherapy (AIT) has shown clinical benefits in patients sensitized to different allergens, studies in asthmatic patients sensitized to olive pollen are insufficient. Objective: To a...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-12-01
|
| Series: | World Allergy Organization Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1939455120303902 |
| _version_ | 1818647893751365632 |
|---|---|
| author | José Fernando Florido-López Carmen Andreu-Balaguer Carmelo Escudero Marta Seoane-Rodríguez Mercedes Hernández Luis Ángel Navarro-Seisdedos Miguel Torrecillas-Toro Mónica Anton-Girones Leticia Herrero-Lifona Dorimar Brugaletta Jesús Macías Rafael Pineda Maria Ángeles Lara Julián López-Caballero Maria José Rojas |
| author_facet | José Fernando Florido-López Carmen Andreu-Balaguer Carmelo Escudero Marta Seoane-Rodríguez Mercedes Hernández Luis Ángel Navarro-Seisdedos Miguel Torrecillas-Toro Mónica Anton-Girones Leticia Herrero-Lifona Dorimar Brugaletta Jesús Macías Rafael Pineda Maria Ángeles Lara Julián López-Caballero Maria José Rojas |
| author_sort | José Fernando Florido-López |
| collection | DOAJ |
| description | Background: Allergy to olive pollen is one of the primary causes of allergic asthma in Spain. Even though allergen immunotherapy (AIT) has shown clinical benefits in patients sensitized to different allergens, studies in asthmatic patients sensitized to olive pollen are insufficient. Objective: To assess the effectiveness and safety of an ultra-short course of AIT with an L-tyrosine-adsorbed and monophosphoryl lipid A-adjuvanted olive pollen and olive/grass pollen extract (Pollinex Quattro®) in patients with allergic asthma in the real-world setting. Methods: Retrospective, controlled study including patients with asthma, with and without allergic rhinitis, caused by sensitization to olive pollen from 11 centers in Spain. Patients received out-of-season (October–March) treatment with AIT in addition to their pharmacological treatment (active group) or pharmacological treatment (control group). Effectiveness variables, including unscheduled visits to the healthcare center, emergency room admissions, symptoms of asthma and rhinitis (following GEMA and ARIA classifications, respectively), and use of medication to treat asthma and rhinitis during the subsequent pollen season were compared between treatment groups. Results: Of 131 study patients, 42 were treated with their usual asthma medication (control group) and 89 were treated with AIT (active group), either Pollinex Quattro® 100% olive pollen (n = 43, 48.3%) or 50% olive pollen/50% grass pollen (n = 46, 51.7%). Patients’ demographic and clinical characteristics were similar between groups. The mean (SD) number of unscheduled visits to a healthcare center and emergency room admissions due to allergy symptoms was 2.19 (1.40) and 0.43 (0.63) in the control group, and 1.09 (1.25) and 0.11 (0.51) in the active group (P = 0.001 and P = 0.006, respectively). Severity and control of asthma symptoms remained unchanged (P = 0.347 and P = 0.179, respectively), rhinitis type improved (P = 0.025), and severity remained unchanged in the active compared to the control group. The use of short-acting beta-agonists and inhaled corticosteroids to treat asthma symptoms decreased in the active vs. the control group (P = 0.001 and P = 0.031, respectively). Twelve (13.5%) and two (2.2%) patients in the active group experienced local adverse reactions (edema, swelling, erythema, hives, pruritus, and heat), and systemic adverse reactions (hypertensive crisis and low-grade fever) to AIT, respectively; none was serious. Conclusion: AIT with Pollinex Quattro® specific for olive pollen and olive/grass pollens resulted in reduced visits to the healthcare center and emergency room and the use of asthma medication during the pollen season, indicating that this treatment was safe and effective in treating asthma in patients sensitized to these pollens. |
| first_indexed | 2024-12-17T01:09:46Z |
| format | Article |
| id | doaj.art-58a19e86760e4eff9092be99fd34f12d |
| institution | Directory Open Access Journal |
| issn | 1939-4551 |
| language | English |
| last_indexed | 2024-12-17T01:09:46Z |
| publishDate | 2020-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | World Allergy Organization Journal |
| spelling | doaj.art-58a19e86760e4eff9092be99fd34f12d2022-12-21T22:09:11ZengElsevierWorld Allergy Organization Journal1939-45512020-12-011312100487Effectiveness and safety of a glutaraldehyde-modified, L-tyrosine-adsorbed and monophosphoryl lipid A-Adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen: A retrospective, controlled real-world studyJosé Fernando Florido-López0Carmen Andreu-Balaguer1Carmelo Escudero2Marta Seoane-Rodríguez3Mercedes Hernández4Luis Ángel Navarro-Seisdedos5Miguel Torrecillas-Toro6Mónica Anton-Girones7Leticia Herrero-Lifona8Dorimar Brugaletta9Jesús Macías10Rafael Pineda11Maria Ángeles Lara12Julián López-Caballero13Maria José Rojas14Hospital Clínico Universitario (Parque Tecnológico de La Salud). Granada, Spain; Corresponding author. Allergology Department, Hospital Clínico Universitario (Parque Tecnológico de la Salud), Avenida de la Investigación, 18016, Granada, Spain.Hospital Comarcal de Orihuela. Alicante, SpainDepartment of Allergy, Hospital Infantil Universitario Niño Jesús, IIS-P, FibHNJ. Madrid, SpainHospital Infanta Elena and Hospital de Valdemoro. Madrid, SpainHospital Nisa Sevilla Aljarafe. Sevilla, SpainHospital Lluis Alcanyís, Xàtiva, Valencia, SpainHospital Perpetuo Socorro – Albacete. Albacete, SpainHospital Universitario de Vinalopó. Alicante, SpainHospital Quirón Málaga. Málaga, SpainHospital Universitario de Vinalopó. Alicante, SpainHospital Arganda. Madrid, SpainHospital Arganda. Madrid, SpainHospital Clínico Universitario (Parque Tecnológico de La Salud). Granada, SpainHospital Vithas Granada. Granada, SpainHospital Clínico Universitario (Parque Tecnológico de La Salud). Granada, SpainBackground: Allergy to olive pollen is one of the primary causes of allergic asthma in Spain. Even though allergen immunotherapy (AIT) has shown clinical benefits in patients sensitized to different allergens, studies in asthmatic patients sensitized to olive pollen are insufficient. Objective: To assess the effectiveness and safety of an ultra-short course of AIT with an L-tyrosine-adsorbed and monophosphoryl lipid A-adjuvanted olive pollen and olive/grass pollen extract (Pollinex Quattro®) in patients with allergic asthma in the real-world setting. Methods: Retrospective, controlled study including patients with asthma, with and without allergic rhinitis, caused by sensitization to olive pollen from 11 centers in Spain. Patients received out-of-season (October–March) treatment with AIT in addition to their pharmacological treatment (active group) or pharmacological treatment (control group). Effectiveness variables, including unscheduled visits to the healthcare center, emergency room admissions, symptoms of asthma and rhinitis (following GEMA and ARIA classifications, respectively), and use of medication to treat asthma and rhinitis during the subsequent pollen season were compared between treatment groups. Results: Of 131 study patients, 42 were treated with their usual asthma medication (control group) and 89 were treated with AIT (active group), either Pollinex Quattro® 100% olive pollen (n = 43, 48.3%) or 50% olive pollen/50% grass pollen (n = 46, 51.7%). Patients’ demographic and clinical characteristics were similar between groups. The mean (SD) number of unscheduled visits to a healthcare center and emergency room admissions due to allergy symptoms was 2.19 (1.40) and 0.43 (0.63) in the control group, and 1.09 (1.25) and 0.11 (0.51) in the active group (P = 0.001 and P = 0.006, respectively). Severity and control of asthma symptoms remained unchanged (P = 0.347 and P = 0.179, respectively), rhinitis type improved (P = 0.025), and severity remained unchanged in the active compared to the control group. The use of short-acting beta-agonists and inhaled corticosteroids to treat asthma symptoms decreased in the active vs. the control group (P = 0.001 and P = 0.031, respectively). Twelve (13.5%) and two (2.2%) patients in the active group experienced local adverse reactions (edema, swelling, erythema, hives, pruritus, and heat), and systemic adverse reactions (hypertensive crisis and low-grade fever) to AIT, respectively; none was serious. Conclusion: AIT with Pollinex Quattro® specific for olive pollen and olive/grass pollens resulted in reduced visits to the healthcare center and emergency room and the use of asthma medication during the pollen season, indicating that this treatment was safe and effective in treating asthma in patients sensitized to these pollens.http://www.sciencedirect.com/science/article/pii/S1939455120303902Allergen immunotherapyOlive pollenAllergic asthmaAllergic rhinitisSubcutaneous immunotherapyMicrocrystalline tyrosine |
| spellingShingle | José Fernando Florido-López Carmen Andreu-Balaguer Carmelo Escudero Marta Seoane-Rodríguez Mercedes Hernández Luis Ángel Navarro-Seisdedos Miguel Torrecillas-Toro Mónica Anton-Girones Leticia Herrero-Lifona Dorimar Brugaletta Jesús Macías Rafael Pineda Maria Ángeles Lara Julián López-Caballero Maria José Rojas Effectiveness and safety of a glutaraldehyde-modified, L-tyrosine-adsorbed and monophosphoryl lipid A-Adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen: A retrospective, controlled real-world study World Allergy Organization Journal Allergen immunotherapy Olive pollen Allergic asthma Allergic rhinitis Subcutaneous immunotherapy Microcrystalline tyrosine |
| title | Effectiveness and safety of a glutaraldehyde-modified, L-tyrosine-adsorbed and monophosphoryl lipid A-Adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen: A retrospective, controlled real-world study |
| title_full | Effectiveness and safety of a glutaraldehyde-modified, L-tyrosine-adsorbed and monophosphoryl lipid A-Adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen: A retrospective, controlled real-world study |
| title_fullStr | Effectiveness and safety of a glutaraldehyde-modified, L-tyrosine-adsorbed and monophosphoryl lipid A-Adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen: A retrospective, controlled real-world study |
| title_full_unstemmed | Effectiveness and safety of a glutaraldehyde-modified, L-tyrosine-adsorbed and monophosphoryl lipid A-Adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen: A retrospective, controlled real-world study |
| title_short | Effectiveness and safety of a glutaraldehyde-modified, L-tyrosine-adsorbed and monophosphoryl lipid A-Adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen: A retrospective, controlled real-world study |
| title_sort | effectiveness and safety of a glutaraldehyde modified l tyrosine adsorbed and monophosphoryl lipid a adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen a retrospective controlled real world study |
| topic | Allergen immunotherapy Olive pollen Allergic asthma Allergic rhinitis Subcutaneous immunotherapy Microcrystalline tyrosine |
| url | http://www.sciencedirect.com/science/article/pii/S1939455120303902 |
| work_keys_str_mv | AT josefernandofloridolopez effectivenessandsafetyofaglutaraldehydemodifiedltyrosineadsorbedandmonophosphoryllipidaadjuvantedallergenimmunotherapyinpatientswithallergicasthmasensitizedtoolivepollenaretrospectivecontrolledrealworldstudy AT carmenandreubalaguer effectivenessandsafetyofaglutaraldehydemodifiedltyrosineadsorbedandmonophosphoryllipidaadjuvantedallergenimmunotherapyinpatientswithallergicasthmasensitizedtoolivepollenaretrospectivecontrolledrealworldstudy AT carmeloescudero effectivenessandsafetyofaglutaraldehydemodifiedltyrosineadsorbedandmonophosphoryllipidaadjuvantedallergenimmunotherapyinpatientswithallergicasthmasensitizedtoolivepollenaretrospectivecontrolledrealworldstudy AT martaseoanerodriguez effectivenessandsafetyofaglutaraldehydemodifiedltyrosineadsorbedandmonophosphoryllipidaadjuvantedallergenimmunotherapyinpatientswithallergicasthmasensitizedtoolivepollenaretrospectivecontrolledrealworldstudy AT mercedeshernandez effectivenessandsafetyofaglutaraldehydemodifiedltyrosineadsorbedandmonophosphoryllipidaadjuvantedallergenimmunotherapyinpatientswithallergicasthmasensitizedtoolivepollenaretrospectivecontrolledrealworldstudy AT luisangelnavarroseisdedos effectivenessandsafetyofaglutaraldehydemodifiedltyrosineadsorbedandmonophosphoryllipidaadjuvantedallergenimmunotherapyinpatientswithallergicasthmasensitizedtoolivepollenaretrospectivecontrolledrealworldstudy AT migueltorrecillastoro effectivenessandsafetyofaglutaraldehydemodifiedltyrosineadsorbedandmonophosphoryllipidaadjuvantedallergenimmunotherapyinpatientswithallergicasthmasensitizedtoolivepollenaretrospectivecontrolledrealworldstudy AT monicaantongirones effectivenessandsafetyofaglutaraldehydemodifiedltyrosineadsorbedandmonophosphoryllipidaadjuvantedallergenimmunotherapyinpatientswithallergicasthmasensitizedtoolivepollenaretrospectivecontrolledrealworldstudy AT leticiaherrerolifona effectivenessandsafetyofaglutaraldehydemodifiedltyrosineadsorbedandmonophosphoryllipidaadjuvantedallergenimmunotherapyinpatientswithallergicasthmasensitizedtoolivepollenaretrospectivecontrolledrealworldstudy AT dorimarbrugaletta effectivenessandsafetyofaglutaraldehydemodifiedltyrosineadsorbedandmonophosphoryllipidaadjuvantedallergenimmunotherapyinpatientswithallergicasthmasensitizedtoolivepollenaretrospectivecontrolledrealworldstudy AT jesusmacias effectivenessandsafetyofaglutaraldehydemodifiedltyrosineadsorbedandmonophosphoryllipidaadjuvantedallergenimmunotherapyinpatientswithallergicasthmasensitizedtoolivepollenaretrospectivecontrolledrealworldstudy AT rafaelpineda effectivenessandsafetyofaglutaraldehydemodifiedltyrosineadsorbedandmonophosphoryllipidaadjuvantedallergenimmunotherapyinpatientswithallergicasthmasensitizedtoolivepollenaretrospectivecontrolledrealworldstudy AT mariaangeleslara effectivenessandsafetyofaglutaraldehydemodifiedltyrosineadsorbedandmonophosphoryllipidaadjuvantedallergenimmunotherapyinpatientswithallergicasthmasensitizedtoolivepollenaretrospectivecontrolledrealworldstudy AT julianlopezcaballero effectivenessandsafetyofaglutaraldehydemodifiedltyrosineadsorbedandmonophosphoryllipidaadjuvantedallergenimmunotherapyinpatientswithallergicasthmasensitizedtoolivepollenaretrospectivecontrolledrealworldstudy AT mariajoserojas effectivenessandsafetyofaglutaraldehydemodifiedltyrosineadsorbedandmonophosphoryllipidaadjuvantedallergenimmunotherapyinpatientswithallergicasthmasensitizedtoolivepollenaretrospectivecontrolledrealworldstudy |